

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Withdrawn) A peptide according to formula 1

(formula 1)  $(X1)_n\text{-A-A-V-A-L-L-P-A-V-L-L-A-L-L-A-P-(X2)}_m$

wherein X1 and X2 are selected from one or more charged amino acid residues such that each X1 and each X2 may be the same or different charged amino acid residue, further wherein n has a value of 0 or 3-10, and m has a value of 0 or 3-10, and if  $m=0$ , n has a value from 4 to 10, and if  $n=0$ , m has a value from 4 to 10.

- 2-6. (Canceled)

7. (Currently Amended) A composition comprising an antiviral peptide, wherein the antiviral peptide is selected from the group consisting of SEQ ID NOS: **1 and 14**, **3-15, SEQ ID NOS 18-30**, fragments thereof and derivatives thereof, wherein the antiviral peptide having SEQ ID NO:1 has an amino terminus selected from the group consisting of a  $\text{NH}_2$  group and a biotin-aminohexanoyl group, and wherein if the antiviral peptide is SEQ ID NO:14, **SEQ ID NO:15**, a fragment or derivative thereof, then X1 and X2 are selected from one or more charged amino acid residues such that each X1 and each X2 may be the same or different charged amino acid residue, further wherein n has a value of 0 or 3-10, and m has a value of 0 or 3-10, and if  $m=0$ , n has a value from 4 to 10, and if  $n=0$ , m has a value from 4 to 10.

8. (Currently Amended) The composition according to claim 7, wherein the antiviral peptide is ~~selected from the group consisting of~~ SEQ ID NO: 1, **NOS: 1, 3-13**, wherein SEQ ID NO:1 has an amino terminus selected from the group consisting of an  $\text{NH}_2$  group and a biotin-aminohexanoyl group.

9. (Withdrawn-Currently Amended) The composition according to claim 7, wherein the antiviral peptide **has SEQ ID. NO:1 and the amino terminus of SEQ ID NO: 1 is an NH<sub>2</sub> group, is selected from the group consisting of SEQ ID NOS: 14-15.**

10. (Withdrawn) The composition according to claim 7, wherein the antiviral peptide is SEQ ID NO:14, wherein m=0 and n has a value of 4 to 10.

11. (Canceled)

12. (Currently amended) The composition according to claim 7[[11]], wherein the composition is effective at treating **or-preventing** infections from one or more viruses selected from the group consisting of human immunodeficiency virus, **and** herpes simplex viruses **and cytomegalovirus.**

13. (Currently Amended) The composition according to claim 12, wherein the composition is effective at treating **or-preventing** infections from one or more herpes simplex viruses.

14. (Canceled).

15. (Withdrawn-Currently Amended) A method of treating **or-preventing** a virus infection in a warm blooded animal comprising administering to the animal an effective amount of the composition according to claim 7, **wherein the infection is from one or more viruses selected from the group consisting of human immunodeficiency virus, and herpes simplex viruses.**

16. (Withdrawn-Currently Amended) A method of treating **or-preventing** a virus infection in a warm blooded animal comprising administering to the animal an effective amount of the composition according to claim 9 **[[10]], wherein the infection is from one or more viruses selected from the group consisting of human immunodeficiency virus, and herpes simplex viruses.**

17. (Previously presented) The peptide of claim 1, wherein X1 and X2 are selected from one or more positively charged amino acid residues such that each X1 and each X2 may be the same or different positively charged amino acid residues.

18. (Canceled)

19. (Previously presented) The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

20. (Previously presented) The composition of claim 7, wherein X1 and X2 are selected from one or more positively charged amino acid residues such that each X1 and each X2 may be the same or different positively charged amino acid residues.

21. (Currently Amended) The composition according to claim 7, wherein the antiviral peptide is SEQ ID NO: 1 ~~selected from the group consisting of SEQ ID NOS: 1, 3-13,~~ and fragments thereof, wherein SEQ ID NO:1 has an amino terminus selected from the group consisting of an NH<sub>2</sub> group and a biotin-aminohexanoyl group.

22. (Currently Amended) The composition according to claim 7, wherein the antiviral peptide is SEQ ID NO: 14 ~~selected from the group consisting of SEQ ID NOS: 14-15,~~ and fragments thereof.